Helus Pharma CEO to Present at H.C. Wainwright Conference
Event summary
- Helus Pharma CEO Michael Halstead to participate in fireside chat at H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026.
- Event to be webcast live at 9:00 a.m. EDT, with replay available on Helus Pharma's investor relations website.
- Helus Pharma is developing HLP003 (Phase 3) for major depressive disorder and HLP004 (Phase 2) for generalized anxiety disorder.
- Company has received Breakthrough Therapy Designation from the FDA for HLP003.
The big picture
Helus Pharma's participation in the H.C. Wainwright conference underscores its push to engage investors as it advances its lead candidates through critical clinical phases. The company's focus on serotonergic agonists positions it in a growing segment of mental health treatments, where regulatory milestones like the FDA's Breakthrough Therapy Designation can significantly impact market perception and valuation. The broader industry is watching how novel mechanisms like NSAs perform in late-stage trials, with implications for the future of depression and anxiety treatment.
What we're watching
- Clinical Progress
- The pace at which Helus Pharma advances HLP003 and HLP004 through clinical trials will determine its near-term valuation.
- Regulatory Dynamics
- Whether the FDA's Breakthrough Therapy Designation for HLP003 accelerates approval timelines and reduces development costs.
- Market Positioning
- How Helus Pharma differentiates its serotonergic agonists in a competitive mental health treatment landscape.